Роль тромбина в патогенезе атеросклероза и его осложнений

Тромбин является ключевым регулятором системы гемостаза. Кроме того, он принимает активное участие в прогрессировании различных системных заболеваний, в том числе атеросклероза. Имеется большое количество полученных в экспериментальных и клинических исследованиях данных о вовлечении тромбина в патогенез ишемической болезни сердца (ИБС). В связи с этим перспективными представляются вопросы регуляции активности тромбина. Кроме того, актуален вопрос о возможности использования биомаркеров активности тромбина в качестве предикторов развития сердечно-сосудистых осложнений у пациентов с ИБС. В данном обзоре литературы рассмотрены основные моменты функционирования тромбина в нормальных физиологических условиях, его роль в развитии и прогрессировании атеросклероза, имеющиеся тесты оценки его функциональной активности, а также проводится обсуждение основных клинических исследований по оценке эффективности ингибиторов тромбина и блокаторов рецепторов, активируемых протеазами.

1. Moravitz P. Beiträge zur kenntnis der blutgerinnung. Deutsches Archiv für klinische Medizin. 1904;79:1–28

2. Davie EW, Ratnoff OD. Waterfall Sequence for Intrinsic Blood Clotting. Science. 1964;145(3638):1310–2. DOI: 10.1126/science.145.3638.1310

3. Macfarlane RG. An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier. Nature. 1964;202(4931):498–9. DOI: 10.1038/202498a0

4. Schastlivtsev I.V., Lobastov K.V., Tsaplin S.N., Mkrtychev D.S. Modern view on hemostasis system: cell theory. Medical Council. 2019;16:72–7. [Russian: Счастливцев И.В., Лобастов К.В., Цаплин С.Н., Мкртычев Д.С. Современный взгляд на систему гемостаза: клеточная теория. Медицинский Совет. 2019;16:72–7]. DOI: 10.21518/2079-701X-2019-16-72-77

5. Hoffman M, Monroe D. A Cell-based Model of Hemostasis. Thrombosis and Haemostasis. 2001;85(6):958–65. DOI: 10.1055/s-0037-1615947

6. Foley JH, Conway EM. Cross Talk Pathways Between Coagulation and Inflammation. Circulation Research. 2016;118(9):1392–408. DOI: 10.1161/CIRCRESAHA.116.306853

7. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS et al. Atherosclerosis. Nature Reviews Disease Primers. 2019;5(1):56. DOI: 10.1038/s41572-019-0106-z

8. Petzold T, Massberg S. Thrombin: A Gas Pedal Driving Innate Immunity. Immunity. 2019;50(4):1024–6. DOI: 10.1016/j.immuni.2019.03.006

9. Davie E, Kulman J. An Overview of the Structure and Function of Thrombin. Seminars in Thrombosis and Hemostasis. 2006;32(Suppl 1):3–15. DOI: 10.1055/s-2006-939550

10. Iannucci J, Renehan W, Grammas P. Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer’s Disease. Frontiers in Neuroscience. 2020;14:762. DOI: 10.3389/fnins.2020.00762

11. Shavit-Stein E, Aronovich R, Sylantiev C, Gofrit SG, Chapman J, Dori A. The role of thrombin in the pathogenesis of diabetic neuropathy. PLOS ONE. 2019;14(7):e0219453. DOI: 10.1371/journal.pone.0219453

12. Winter WE, Greene DN, Beal SG, Isom JA, Manning H, Wilkerson G et al. Clotting factors: Clinical biochemistry and their roles as plasma enzymes. Advances in Clinical Chemistry. 2020;94:31–84. DOI: 10.1016/bs.acc.2019.07.008

13. Borissoff JI, Spronk HMH, Heeneman S, ten Cate H. Is thrombin a key player in the ‘coagulation-atherogenesis’ maze? Cardiovascular Research. 2009;82(3):392–403. DOI: 10.1093/cvr/cvp066

14. Wu J, Heemskerk JWM, Baaten CCFMJ. Platelet Membrane Receptor Proteolysis: Implications for Platelet Function. Frontiers in Cardiovascular Medicine. 2021;7:608391. DOI: 10.3389/fcvm.2020.608391

15. Kretz CA, Tomberg K, Van Esbroeck A, Yee A, Ginsburg D. High throughput protease profiling comprehensively defines active site specificity for thrombin and ADAMTS13. Scientific Reports. 2018;8(1):2788. DOI: 10.1038/s41598-018-21021-9

16. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015;125(19):2898–907. DOI: 10.1182/blood-2015-02-355974

17. Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis Journal. 2019;17(1):4. DOI: 10.1186/s12959-019-0194-8

18. Posma JJN, Posthuma JJ, Spronk HMH. Coagulation and non-coagulation effects of thrombin. Journal of Thrombosis and Haemostasis. 2016;14(10):1908–16. DOI: 10.1111/jth.13441

19. Posma JJ, Grover SP, Hisada Y, Owens AP, Antoniak S, Spronk HM et al. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(1):13–24. DOI: 10.1161/ATVBAHA.118.311655

20. Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M et al. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nature Communications. 2015;6(1):7835. DOI: 10.1038/ncomms8835

21. Burzynski LC, Humphry M, Pyrillou K, Wiggins KA, Chan JNE, Figg N et al. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin. Immunity. 2019;50(4):1033-1042.e6. DOI: 10.1016/j.immuni.2019.03.003

22. Fang X, Liao R, Yu Y, Li J, Guo Z, Zhu T. Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line. Mediators of Inflammation. 2019;2019:4952131. DOI: 10.1155/2019/4952131

23. Miszta A, Pelkmans L, Lindhout T, Krishnamoorthy G, de Groot PG, Hemker CH et al. Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network. Journal of Biological Chemistry. 2014;289(52):35979–86. DOI: 10.1074/jbc.M114.591677

24. Janjanam J, Zhang B, Mani AM, Singh NK, Traylor JG, Orr AW et al. LIM and cysteine-rich domains 1 is required for thrombin-induced smooth muscle cell proliferation and promotes atherogenesis. Journal of Biological Chemistry. 2018;293(9):3088–103. DOI: 10.1074/jbc.RA117.000866

25. Jaberi N, Soleimani A, Pashirzad M, Abdeahad H, Mohammadi F, Khoshakhlagh M et al. Role of thrombin in the pathogenesis of atherosclerosis. Journal of Cellular Biochemistry. 2019;120(4):4757–65. DOI: 10.1002/jcb.27771

26. Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. American Journal of Physiology-Cell Physiology. 1997;273(1):C239–45. DOI: 10.1152/ajpcell.1997.273.1.C239

27. Wang Z. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. Journal of Molecular and Cellular Cardiology. 2004;36(1):49–56. DOI: 10.1016/j.yjmcc.2003.09.014

28. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021;397(10285):1637–45. DOI: 10.1016/S0140-6736(21)00676-0

29. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME et al. Melagatran Reduces Advanced Atherosclerotic Lesion Size and May Promote Plaque Stability in Apolipoprotein E– Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(12):2787–92. DOI: 10.1161/01.ATV.0000246797.05781.ad

30. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma. Pathophysiology of Haemostasis and Thrombosis. 2003;33(1):4–15. DOI: 10.1159/000071636

31. Loeffen R, van Oerle R, Leers MPG, Kragten JA, Crijns H, Spronk HMH et al. Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recur-